{"id":436725,"date":"2017-03-16T20:05:00","date_gmt":"2017-03-16T20:05:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=fadb2dc261b0daea314784b1d6ee217c"},"modified":"2017-03-16T20:05:00","modified_gmt":"2017-03-16T20:05:00","slug":"curis-to-present-at-the-oppenheimer-co-inc-27th-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/curis-to-present-at-the-oppenheimer-co-inc-27th-annual-healthcare-conference\/","title":{"rendered":"Curis to Present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference"},"content":{"rendered":"

LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) — March 16, 2017 – Curis, Inc. (NASDAQ:CRIS<\/a>), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that James Dentzer, Chief Financial Officer and Chief Administrative Officer, will present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference on March 21, 2017 at 2:10 p.m. Eastern Time in New York.<\/p>\n

A corresponding webcast of the presentation can be accessed, both live and archived, by visiting:<\/p>\n

https:\/\/www.veracast.com\/webcasts\/opco\/healthcare2017\/03110203347.cfm<\/a><\/p>\n

The webcast will be archived shortly after the live event and will be available for 90 days through June 19, 2017. It will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com<\/a>.<\/p>\n

About Curis, Inc.<\/strong><\/p>\n

Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.  Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1\/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1\/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.  Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge\u00ae for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis’s website at www.curis.com<\/a>.<\/p>\n

CONTACT: For More Information:\nJames E. Dentzer\nChief Financial Officer & Chief Administrative Officer\nCuris, Inc.\n617-503-6597\njdentzer@curis.com\n\nMedia Contact\nDavid Schull\nRusso Partners\n(212) 845-4271\ndavid.schull@russopartnersllc.com<\/pre>\n","protected":false},"excerpt":{"rendered":"
LEXINGTON, Mass., March  16, 2017  (GLOBE NEWSWIRE) — March 16, 2017 – Curis, Inc. (NASDAQ:CRIS<\/a>), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that James Dentzer, Chief Financial Officer and Chief Administrative Officer, will present at the Oppenheimer & Co. Inc. 27th Annual Healthcare Conference on March 21, 2017 at 2:10 p.m. Eastern Time in New York.<\/p>\n
A corresponding webcast of the presentation can be accessed, both live and archived, by visiting:<\/p>\n
https:\/\/www.veracast.com\/webcasts\/opco\/healthcare2017\/03110203347.cfm<\/a><\/p>\n
The webcast will be archived shortly after the live event and will be available for 90 days through June 19, 2017. It will also be available for 30 days on the Investor Relations section of the Curis website at www.curis.com<\/a>.<\/p>\n
About Curis, Inc.<\/strong><\/p>\n
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors.  Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology.  As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1\/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1\/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948.  Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis’s website at www.curis.com<\/a>.<\/p>\n
CONTACT: For More Information:\nJames E. Dentzer\nChief Financial Officer & Chief Administrative Officer\nCuris, Inc.\n617-503-6597\njdentzer@curis.com\n\nMedia Contact\nDavid Schull\nRusso Partners\n(212) 845-4271\ndavid.schull@russopartnersllc.com<\/pre>\n","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/436725"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=436725"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/436725\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=436725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=436725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=436725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}